 TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
| Descriptor ID |
D058570
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
| Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- Mechanistic Target of Rapamycin Protein
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- TOR Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 6 | 6 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 11 | 11 | | 2009 | 0 | 11 | 11 | | 2010 | 5 | 6 | 11 | | 2011 | 6 | 6 | 12 | | 2012 | 7 | 9 | 16 | | 2013 | 9 | 8 | 17 | | 2014 | 15 | 8 | 23 | | 2015 | 9 | 10 | 19 | | 2016 | 4 | 8 | 12 | | 2017 | 8 | 7 | 15 | | 2018 | 3 | 7 | 10 | | 2019 | 4 | 6 | 10 | | 2020 | 6 | 10 | 16 | | 2021 | 4 | 5 | 9 | | 2022 | 1 | 7 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 Sep 06; 21(9):1381-1392.
-
Lai D, Gade M, Yang E, Koh HY, Lu J, Walley NM, Buckley AF, Sands TT, Akman CI, Mikati MA, McKhann GM, Goldman JE, Canoll P, Alexander AL, Park KL, Von Allmen GK, Rodziyevska O, Bhattacharjee MB, Lidov HGW, Vogel H, Grant GA, Porter BE, Poduri AH, Crino PB, Heinzen EL. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations. Brain. 2022 08 27; 145(8):2704-2720.
-
Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
-
Lamontagne JO, Zhang H, Zeid AM, Strittmatter K, Rocha AD, Williams T, Zhang S, Marneros AG. Transcription factors AP-2a and AP-2ß regulate distinct segments of the distal nephron in the mammalian kidney. Nat Commun. 2022 04 25; 13(1):2226.
-
Masuda M, Yoshida-Shimizu R, Mori Y, Ohnishi K, Adachi Y, Sakai M, Kabutoya S, Ohminami H, Yamanaka-Okumura H, Yamamoto H, Miyazaki M, Taketani Y. Sulforaphane induces lipophagy through the activation of AMPK-mTOR-ULK1 pathway signaling in adipocytes. J Nutr Biochem. 2022 08; 106:109017.
-
Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, Byrareddy SN. PI3K-a/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin Transl Med. 2022 04; 12(4):e806.
-
Francis EC, Dabelea D, Boyle KE, Jansson T, Perng W. Maternal Diet Quality Is Associated with Placental Proteins in the Placental Insulin/Growth Factor, Environmental Stress, Inflammation, and mTOR Signaling Pathways: The Healthy Start ECHO Cohort. J Nutr. 2022 03 03; 152(3):816-825.
-
Khandker L, Jeffries MA, Chang YJ, Mather ML, Evangelou AV, Bourne JN, Tafreshi AK, Ornelas IM, Bozdagi-Gunal O, Macklin WB, Wood TL. Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord. Cell Rep. 2022 03 01; 38(9):110423.
-
Petrache I, de Boer E. Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury. Am J Respir Cell Mol Biol. 2021 12; 65(6):576-577.
-
Jeffries MA, McLane LE, Khandker L, Mather ML, Evangelou AV, Kantak D, Bourne JN, Macklin WB, Wood TL. mTOR Signaling Regulates Metabolic Function in Oligodendrocyte Precursor Cells and Promotes Efficient Brain Remyelination in the Cuprizone Model. J Neurosci. 2021 10 06; 41(40):8321-8337.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|